More time is needed to gauge whether FDA's rare pediatric disease priority review voucher program has actually encouraged the development of new treatments, the Government Accountability Office believes.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?